Last reviewed · How we verify
Sing2016 M2SR H3N2 influenza vaccine
At a glance
| Generic name | Sing2016 M2SR H3N2 influenza vaccine |
|---|---|
| Sponsor | FluGen Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (PHASE1)
- Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old (PHASE1)
- Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sing2016 M2SR H3N2 influenza vaccine CI brief — competitive landscape report
- Sing2016 M2SR H3N2 influenza vaccine updates RSS · CI watch RSS
- FluGen Inc portfolio CI